Icosapent ethyl in cardiovascular prevention: Resolution of inflammation through the eicosapentaenoic acid - resolvin E1 - ChemR23 axis
CVOT
cardiovascular outcome trials
CCTA
coronary computed tomographic angiography
FADS
fatty acid desaturases
GPR
G protein-coupled receptors
HEPE
hydroxyeicosapentaenoic acid
LDL
low-density lipoprotein
MACE
major adverse cardiovascular events
oxLDL
oxidized low-density lipoprotein
PUFA
polyunsaturated fatty acids
SNP
single-nucleotide polymorphism
SPM
specialized proresolving mediator
留言 (0)